Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epilepsy
Biotech
J&J calls time on Addex partnership a year after epilepsy fail
Nine months after J&J stepped back from an Addex-partnered epilepsy drug in the wake of a phase 2 fail, the pharma has now severed the relationship.
James Waldron
Apr 17, 2025 7:05am
Atalanta’s RNA epilepsy asset suppresses seizures in mice
Apr 10, 2025 5:30am
Cell therapy biotech bags $102M to fund phase 3 epilepsy plans
Apr 3, 2025 1:22pm
Encoded lays off 29% of staff to fund Dravet gene therapy trial
Feb 13, 2025 10:20am
Takeda axes epilepsy asset after FDA weighs in on data package
Jan 30, 2025 7:19am
Atalanta loads crossbow with $97M, 2 Big Pharmas in tow
Jan 28, 2025 7:00am
